Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 1
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.
Vesterhus M, Hov JR, Holm A, Schrumpf E, Nygård S, Godang K, Andersen IM, Naess S, Thorburn D, Saffioti F, Vatn M, Gilja OH, Lund-Johansen F, Syversveen T, Brabrand K, Parés A, Ponsioen CY, Pinzani M, Färkkilä M, Moum B, Ueland T, Røsjø H, Rosenberg W, Boberg KM, Karlsen TH. Vesterhus M, et al. Hepatology. 2015 Jul;62(1):188-97. doi: 10.1002/hep.27825. Epub 2015 Apr 28. Hepatology. 2015. PMID: 25833813
There is a need to determine biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis (PSC). We evaluated the prognostic utility of the enhanced liver fibrosis (ELF) score in Norwegian PSC patients. .. …
There is a need to determine biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis (PS …
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis.
Dhillon AK, Kremer AE, Kummen M, Boberg KM, Elferink RPO, Karlsen TH, Beuers U, Vesterhus M, Hov JR. Dhillon AK, et al. Sci Rep. 2019 Jun 11;9(1):8450. doi: 10.1038/s41598-019-44762-7. Sci Rep. 2019. PMID: 31186435 Free PMC article.
In a multivariable analysis, high autotaxin activity was associated with an increased risk of liver transplantation or death (hazard ratio 2.03 (95% confidence interval 1.21-3.40), P < 0.01), independent from Mayo risk score, an in-house enhanced liver
In a multivariable analysis, high autotaxin activity was associated with an increased risk of liver transplantation or death (hazard …
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis.
Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, Thorbjørnsen LW, Paulsen V, Lundin K, Dale I, Gilja OH, Zweers SJLB, Vatn M, Schaap FG, Jansen PLM, Ueland T, Røsjø H, Moum B, Ponsioen CY, Boberg KM, Färkkilä M, Karlsen TH, Lund-Johansen F. Vesterhus M, et al. J Hepatol. 2017 Jun;66(6):1214-1222. doi: 10.1016/j.jhep.2017.01.019. Epub 2017 Feb 2. J Hepatol. 2017. PMID: 28161472
BACKGROUND & AIMS: Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and the development of therapy. ...However, the Enhanced Liver Fibrosis (ELF®) test and Mayo risk score proved to be …
BACKGROUND & AIMS: Prognostic biomarkers are lacking in primary sclerosing cholangitis, hampering patient care and …
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, Mayo MJ, Muir AJ, Trotter JF, Leeming DJ, Karsdal MA, Jaros MJ, Ling L, Kim KH, Rossi SJ, Somaratne RM, DePaoli AM, Beuers U. Hirschfield GM, et al. J Hepatol. 2019 Mar;70(3):483-493. doi: 10.1016/j.jhep.2018.10.035. Epub 2018 Nov 9. J Hepatol. 2019. PMID: 30414864 Free article.
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic liver disease devoid of effective medical intervention. ...Importantly, fibrosis biomarkers that predict transplant
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic …
Feedback